Covid-19: pharmacy giant Bayer to produce CureVac vaccine

2021-02-01T09:52:57.417Z

The target is to produce 160 million doses of the vaccine in 2022. The German pharmacy giant Bayer will produce from 2022 the vaccine against Covid-19 developed by its compatriot CureVac, announced Monday the director of the pharmaceutical branch of the group. Read also: Covid-19: vaccine deliveries reduced “ We have the skills to produce the CureVac mRNA vaccine ,” Stefan Oelrich told an online conference, adding that the goal was to produce 160 million doses